MedDataX Logo

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

NCT ID: NCT01323257

Last Updated: 2012-10-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of steady-state concentrations of erythromycin or DRV/r on the steady-state pharmacokinetics of TMC435, the effect of a steady-state concentration of TMC435 (150 mg) on the steady-state pharmacokinetics of erythromycin and the effect of a steady-state concentration of TMC435 (50 mg) on the steady-state pharmacokinetics of DRV/r. We will also study the short-term safety and tolerability of TMC435 given alone and given togehter with erythromycin (Panel 1) or DRV/r (Panel 2). Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Erythromycin is an antibiotic and Darunavir/ritonavir (DRV/r) is currently indicated for the treatment of HIV infection. TMC435 is metabolized by the degradation enzyme CYP3A. Erythromycin and DRV/r are respectively moderate and strong inhibitors of the degradation enzyme CYP3A. The result of this study will provide dosing recommendations for TMC435 and for erythromycin or DRV/r, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 48 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and DRV/r or erythromycin, at steady-state. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive three treatments (Trts A, B and C) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt A) and erythromycin 500 mg three times daily for 6 days + a morning dose on day 7 (Trt B) and TMC435 150 mg once daily for 7 days + erythromycin 500 mg three tmes daily for 7 days (Trt C). In Panel 2, volunteers will receive three treatments (Trts D, E and F) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt D), DRV/r 800/100 mg once daily for 7 days (Trt E) and TMC435 50 mg once daily for 7 days + DRV/r 800/100 mg once daly for 7 days (Trt F). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 10 (Panel 1) or 7 (Panel 2) days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all four compounds (TMC435, DRV, ritonavir and erythromycin) will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, on Day 1, Day 7 and Day 8 and at the follow up visit at 1 week after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) or Day 1, on Day 8 and during the follow-up visit. Volnteers will be admitted to the unit on Day-1, discharged on Day2, re-admitted on Day6 and discharged again on Day8. Each volunteer follows 3 treatment (Trt) periods, which are a minimum 10 days (Panel 1) or 7 days (Panel 2) apart from each other. All treatment periods take 7 days and all drugs are for oral intake. Panel 1: Trt A = 150 mg TMC435 once daily; Trt B = 500 mg erythromycin three times daily; Trt C: combining Trt A + B. Panel 2: Trt D = Trt A; Trt E = 800/100 mg DRV/r once daily; Trt D = 50 mg TMC435 once daily + Trt E.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Virus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

TMC435-TiDP16-C115 TMC435-C115 TMC435 HCV Hepatitis C Hep C healthy volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

TMC435 150 mg capsule once daily for 7 days (Trt A C D)

Group Type EXPERIMENTAL

TMC435

Intervention Type DRUG

150 mg capsule once daily for 7 days (Trt A, C, D)

002

erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

Group Type EXPERIMENTAL

erythromycin

Intervention Type DRUG

500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

003

erythromycin 500 mg tablets three times a day for 7 days (Trt C)

Group Type EXPERIMENTAL

erythromycin

Intervention Type DRUG

500 mg tablets three times a day for 7 days (Trt C)

004

TMC435 50 mg capsule once daily for 7 days (Trt F)

Group Type EXPERIMENTAL

TMC435

Intervention Type DRUG

50 mg capsule once daily for 7 days (Trt F)

005

Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)

Group Type EXPERIMENTAL

Darunavir

Intervention Type DRUG

2 x 400 mg tablet once daily for 7 days (Trt E, F)

006

Ritonavir 100 mg tablet once daily for 7 days (Trt E F)

Group Type EXPERIMENTAL

Ritonavir

Intervention Type DRUG

100 mg tablet once daily for 7 days (Trt E, F)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erythromycin

500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

Intervention Type DRUG

Ritonavir

100 mg tablet once daily for 7 days (Trt E, F)

Intervention Type DRUG

TMC435

150 mg capsule once daily for 7 days (Trt A, C, D)

Intervention Type DRUG

Darunavir

2 x 400 mg tablet once daily for 7 days (Trt E, F)

Intervention Type DRUG

TMC435

50 mg capsule once daily for 7 days (Trt F)

Intervention Type DRUG

erythromycin

500 mg tablets three times a day for 7 days (Trt C)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smoker for at least 3 months
* Body Mass Index of 18.0 to 30.0 kg/m2
* Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram

Exclusion Criteria

* Infection with hepatitis A, B or C virus
* Infection with the human immunodeficiency virus (HIV)
* History of or any current medical condition which could impact the safety of the participant in the study
* Having previously been dosed with TMC435 in a multiple-dose trial with TMC435
* Having previously been dosed with TMC435 in more than 3 single-dose trials with TMC435
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tibotec Pharmaceuticals, Ireland

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tibotec Pharmaceuticals Clinical Trial

Role: STUDY_DIRECTOR

Tibotec Pharmaceutical Limited

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Antwerp, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMC435-TiDP16-C115

Identifier Type: -

Identifier Source: secondary_id

CR018010

Identifier Type: -

Identifier Source: org_study_id